Conectar
To estimate the prevalence of loneliness, social isolation, and their co-occurrence among people living with HIV and to explore factors explaining heterogeneity between estimates.
A systematic review and meta-analysis.
PubMed, Cochrane Library, SciELO Citation Index (via Web of Science), Scopus, Embase, PsycArticles, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from inception until November 1, 2024 for relevant studies.
Study eligibility, data extraction, and methodological quality assessment were conducted independently by two reviewers. Random-effects meta-analysis was used to estimate pooled prevalence. Subgroup analyses were performed.
A total of 66 studies were included. The pooled prevalence of loneliness was 46.9% and that of social isolation was 25.9%. However, heterogeneity was very high across studies, and these pooled estimates should therefore be interpreted cautiously. Subgroup analyses suggested regional variation in both loneliness and social isolation. Other subgroup findings should be interpreted cautiously because some subgroup estimates were based on small numbers of studies.
Loneliness and social isolation are highly prevalent among people living with HIV. Population-specific intervention strategies are needed to reduce this burden, and future studies should further examine contextual and demographic differences to guide intervention design.
Routine HIV services should include screening and referral pathways for loneliness and social isolation.
This systematic review identified the pooled prevalence of loneliness and social isolation among people living with HIV, highlighting a substantial and clinically relevant burden. The findings may influence HIV nurses' practice and inform care approaches for other clinical populations experiencing loneliness and social isolation.
This systematic review followed the PRISMA and MOOSE reporting guidelines.
No patient or public contribution.
by Ting Zhao, Yulin Wang, Fu-an Lin
BackgroundSystemic sclerosis–associated interstitial lung disease (SSc-ILD) is a major clinical challenge with no effective treatments. It is also the leading cause of death in patients with systemic sclerosis. Thus, understanding its underlying molecular mechanisms, particularly those related to macrophage-related gene functions, is critical to address this urgent medical need.
MethodsIn this study, single-cell and transcriptomic data retrieved from a public database were analyzed to investigate the underlying molecular mechanisms of SSc-ILD. A series of comprehensive analyses was conducted, including cell–cell communication analysis, pseudotime trajectory analysis, and high-dimensional weighted gene co-expression network analysis, to identify pertinent genes linked to macrophage modules. Candidate genes were determined by intersecting differentially expressed genes (DEGs) with macrophage module genes. Subsequently, key genes were identified through protein–protein interaction (PPI) network analysis and gene expression validation. Various analytical procedures were used to evaluate the function of the key genes in the regulatory roles of SSc-ILD, including enrichment analysis, immune infiltration analysis, drug prediction, and molecular docking.
ResultsOf the 1515 DEGs and 400 macrophage module genes intersected, 50 candidate genes were identified. In particular, ARG2, ELF3, and NKX2–1 emerged as key genes through subsequent PPI network analyses and gene expression evaluations. Enrichment analyses revealed a notable co-enrichment of the lysosomal pathway with these key genes. Moreover, immune infiltration analysis revealed a strong negative correlation between NKX2–1 and monocytes, whereas ELF3 and ARG2 exhibited a positive association with activated dendritic cells. The molecular docking results showed that the binding energies of ARG2-SKA-111/cyclophosphamide and ELF3–voruciclib/cyclophosphamide were less than − 5 kcal/mol.
ConclusionThe findings of this study highlight the key roles of ARG2, ELF3, and NKX2−1 in macrophage-related mechanisms of SSc-ILD, providing insights into potential therapeutic targets. Further research is necessary to explore their functional implications in disease progression and treatment.
Improving global access to pain management medications for cancer patients remains a critical priority. Nurses are now understood to play an essential role in cancer pain medication management, yet the barriers and facilitators they encounter require urgent identification.
This systematic review aimed to identify the barriers and facilitators for nurses in managing cancer pain medication.
This systematic review followed the Joanna Briggs Institute (JBI)'s guidelines for qualitative systematic reviews.
Eleven databases (PubMed, Web of Science, the Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Scopus, OPENGREY.EU, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal Database (VIP) and SinoMed) were searched from their inception to 9th July 2025. Articles were evaluated for quality using JBI critical appraisal tools. Data extraction was performed according to JBI standardised protocols, and evidence synthesis was conducted using JBI meta-aggregation, which involved extracting findings, categorising them into thematic groups and synthesising them into comprehensive statements.
Twenty-four qualitative studies were reviewed in the present study. Two synthesised findings regarding the barriers and facilitators for nurses in managing cancer pain medication were integrated: (1) Barriers for nurses to manage cancer pain medication were summarised into five categories: systemic barriers, resource barriers, knowledge and skills barriers, financial and cultural barriers and communication and psychological barriers; (2) Facilitators for nurses to manage cancer pain medication were summarised into three categories: nursing capacity building, supportive care environments and collaborative support systems.
Multilevel barriers impede nurse-led cancer pain management, necessitating policy reforms (e.g., tiered prescribing), investments in telehealth/training and culturally responsive interprofessional collaboration. Prioritising facilitators, capacity building, supportive environments and collaboration is vital to empower nurses in delivering equitable, evidence-based pain relief.
This review equips clinical managers and policymakers with evidence to implement policy and practice reforms, such as tiered prescribing and interprofessional collaboration, which are critical to empower nurses in delivering effective cancer pain management.
This systematic review was prospectively registered in PROSPERO prior to the initiation of the search (Registration ID: CRD42024570807).
There was no patient or public contribution.
FreshRSS 